DOJ eyes Ranbaxy pricing

Share this content:

Generic drug manufacturer Ranbaxy, which is currently under an FDA export ban, has now attracted attention from the Department of Justice.

Bloomberg reports that the DOJ is examining the prices the generic maker charged Medicaid. Bloomberg notes that the civil investigative demand does not assert wrongdoing, but also notes that this is just one of a series of run-ins the company has had with US authorities, including a Medicaid fraud investigation in Texas that was settled for $19.5 million.

Share this content:
Scroll down to see the next article